Tag Archive for: M&A

money changing hand
M&A

Can Sanofi buy its way into in vivo CAR-T?

,

Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from a sequence of acquisitions that brought together the key ingredients for in vivo cell engineering: mRNA payloads, lipid nanoparticle delivery, and targeted immune-cell guidance. Across big pharma, companies are increasingly assembling in vivo CAR-T platforms piece by piece, raising a broader question about whether the next generation of cell therapy will be built in-house, or bought.

Read more
muscular distrophy Servier
M&A

Servier buys Edgewise muscular dystrophy business for up to US$2.65bn

French pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, giving the Paris-based company a late-stage entry into Becker and Duchenne muscular dystrophy.

Read more
T-cell attacking a cancer cellROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.com
M&A

T-CURX buys Pantherna as the race for in vivo CAR-T gathers pace

T-CURX acquires Pantherna: does this mark the start of a new race for the next generation of CAR-T therapies? The Würzburg- and Munich-based CAR-T company T-CURX is acquiring the Berlin-based mRNA and LNP company Pantherna Therapeutics. Financial details of the transaction were not disclosed. Pantherna is to continue operating in Hennigsdorf as a wholly owned subsidiary.

Read more
oleg-ivanov-0gWzPSdIwsE-unsplash
M&A

Angelini inks $4.1B Catalyst takeover to fuel US expansion

Italy’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market.

Read more
UCB Candid Bio acquisition
M&A

UCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager push

Belgian biopharma UCB has moved quickly from testing the waters in autoimmune T-cell engagers to making one of the largest bets yet on the modality, agreeing to acquire San Diego-based Candid Therapeutics for up to US$2.2bn.

Read more
Lilly Centessa acquisition
M&A

Lilly moves deeper into sleep medicine with up to $7.8 billion Centessa deal

Eli Lilly has agreed to acquire UK-based Centessa Pharmaceuticals in a deal worth up to $7.8 billion, giving the pharma giant a high-profile entry into one of biotech’s most closely watched neuroscience fields: orexin biology. The companies announced a definitive agreement on March 31, 2026.

Read more
Enodia protein degradation
M&A

Enodia strikes up to $127m deal for Kezar’s preclinical protein degradation assets

Paris-based Enodia Therapeutics announced the acquisition of preclinical assets from San Francisco-based Kezar Life Sciences’ pipeline. Both companies are developers of small molecules that target protein degradation, a field that is attracting significant attention for its potential to treat previously intractable diseases.

Read more
primary biliary cholangitis Alfasigma
M&A

Alfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decision

Italian drugmaker Alfasigma has struck a licensing deal to take over global rights to linerixibat, GSK’s late-stage candidate for cholestatic pruritus in primary biliary cholangitis (PBC), in a transaction that could be worth up to $690 million to the British pharma group. Under the agreement, GSK will receive $300 million upfront, with additional regulatory and commercial milestones plus tiered double-digit royalties on worldwide sales.

Read more
eb-20260309-mohamed-nohassi-Jthv-V45G0E-unsplashUnsplash+
M&A

Servier buys Day One for $2.5bn to bolster its rare cancer pipeline

French pharma giant Servier is spending US$2.5bn to snap up Day One Biopharmaceuticals, gaining a key approved drug for difficult childhood brain tumours along with several promising pipeline candidates.

Read more
aicuris japan flag
M&A

Japan’s Asahi Kasei buys antiviral specialist Aicuris in €780 million deal

Takeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 million (around US$920 million). The company, founded by former Bayer employees Helga Rübsamen-Schaeff and Holger Zimmermann using substances from Bayer, had obtained its own approval and is currently in late-stage clinical development with active ingredients that are currently being presented with positive data at scientific conferences.

Read more